DocWire News Editors

DocwireNews

<h2 class="entry-title">Addition of Apalutamide to ADT Improves Survival in Castration-Resistant Prostate Cancer<p>In previously reported data from the randomized, placebo-controlled, phase III SPARTAN study, researchers found that the addition of apalutamide to ongoing androgen deprivation therapy (ADT) improved metastasis-free survival (MFS) by more than two years in patients with high-risk non-metastatic castration-resistant prostate cancer and prostate-specific antigen doubling time of 10 months or less. The addition of apalutamide also reduced the risk of symptomatic progression by 55% and increased second progression-free survival (PFS2; time from randomization to disease progression on first subsequent anticancer treatment or death).</p><p><a href="https://www.docwirenews.com/conference-coverage/asco-2019/addition-of-apalutamide-adt-improves/">Read More</a></p><h2 class="entry-title">Lenalidomide Improves Survival in Smoldering MM Compared with Observation</h2><p>The standard of care for smoldering multiple myeloma (SMM), a precursor to MM, is observation. However, a 2015 study published in&nbsp;<em>The New England Journal of Medicine</em>suggests that lenalidomide plus dexamethasone improves time to progression of MM and overall survival (OS) for patients with high-risk SMM compared with observation. However, the study had some limitations that weakened the adoption of this regimen as standard of care: Patients were not screened with advanced imaging techniques, it used a definition of high-risk disease that is not routinely available, and combination therapy limited the ability to isolate the effect of lenalidomide.</p><p><a href="https://www.docwirenews.com/conference-coverage/asco-2019/lenalidomide-improves-survival-smoldering/">Read More</a></p><h2 class="entry-title">Diet Impacts Breast Cancer Mortality in Postmenopausal Women</h2><p>Research presented at the&nbsp;<a href="https://www.docwirenews.com/category/conference-coverage/asco-2019/">2019 ASCO Annual Meeting</a>&nbsp;found that a balanced, low-fat diet significantly lowers the risk of breast cancer mortality in postmenopausal women.</p><p>The randomized, controlled Women&rsquo;s Health Initiative Dietary Modification clinical trial was conducted at 40 U.S. centers and included 48,835 postmenopausal women who were 50 to 79 years. Participants did not previously have breast cancer, and they had a dietary fat intake of &ge;32% of total daily calories.</p><p>Between 1993 and 1998, women were randomized to a usual diet comparison group (60%) or dietary intervention group (40%) that aimed to reduce fat intake to 20% of daily calories and increase the intake of vegetables, fruits, and grains.</p><p><a href="https://www.docwirenews.com/conference-coverage/asco-2019/diet-impacts-breast-cancer/">Read More</a></p><h2 class="entry-title">Entrectinib Produces Response in Children with Refractory CNS Tumors</h2><p>Entrectinib is a central nervous system (CNS)-penetrant oral inhibitor of tropomyosin receptor kinase (TRK), ROS1, and anaplastic lymphoma kinase (ALK) tyrosine kinases. Research presented at the&nbsp;<a href="https://www.docwirenews.com/category/conference-coverage/asco-2019/">2019 ASCO Annual Meeting</a>&nbsp;found that first-line use of entrectinib in children with refractory CNS and solid tumors harboring&nbsp;<em>NTRK1/2/3</em>,&nbsp;<em>ROS1</em>,&nbsp;or&nbsp;<em>ALK</em>&nbsp;fusions &ldquo;produced striking, rapid, and durable responses.&rdquo;</p><p>The open-label, dose-escalation, phase I/II STARTRK-NG study included patients &le;20 years with recurrent/refractory solid tumors. Researchers determined a recommended dose in each patient and enrolled disease-specific expansion cohorts of CNS and solid tumors harboring target aberrations in&nbsp;<em>NTRK1/2/3</em>,&nbsp;<em>ROS1</em>,&nbsp;or&nbsp;<em>ALK</em>&nbsp;and neuroblastoma (NBL), regardless of mutation spectrum.</p><p><a href="https://www.docwirenews.com/conference-coverage/asco-2019/entrectinib-produces-response-children/">Read More</a></p><h3><a href="https://www.docwirenews.com/asco-2019/">For Full Coverage of ASCO 2019 Click here</a></h3></h2>


Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Latest News from ASCO 2019: June 11, 2019

ASCO 2019

Addition of Apalutamide to ADT Improves Survival in Castration-Resistant Prostate Cancer ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe